Literature DB >> 1943250

Vancomycin.

M P Wilhelm1.   

Abstract

Vancomycin is a glycopeptide antibiotic that is active against staphylococci, streptococci, and other gram-positive bacteria. It is the drug of choice for the treatment of infections due to methicillin-resistant staphylococci, Corynebacterium jeikeium, and multiply resistant strains of Streptococcus pneumoniae. Vancomycin is an alternative treatment for serious staphylococcal and streptococcal infections, including endocarditis, when allergy precludes the use of penicillins and cephalosporins. Vancomycin is bactericidal against most strains of staphylococci and nonenterococcal streptococci. Although rare strains of staphylococci and enterococci that are resistant to vancomycin have been reported, bacterial resistance has thus far not emerged as a major clinical problem despite widespread use of vancomycin. When therapy is monitored by periodic determinations of serum concentrations of the drug and rapid infusion rates are avoided, vancomycin is rarely associated with serious toxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1943250     DOI: 10.1016/s0025-6196(12)65799-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  14 in total

1.  Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy.

Authors:  Sazid Hussain; Jinmyoung Joo; Jinyoung Kang; Byungji Kim; Gary B Braun; Zhi-Gang She; Dokyoung Kim; Aman P Mann; Tarmo Mölder; Tambet Teesalu; Santina Carnazza; Salvatore Guglielmino; Michael J Sailor; Erkki Ruoslahti
Journal:  Nat Biomed Eng       Date:  2018-01-22       Impact factor: 25.671

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12.

Authors:  A Haldimann; S L Fisher; L L Daniels; C T Walsh; B L Wanner
Journal:  J Bacteriol       Date:  1997-09       Impact factor: 3.490

4.  Use of vancomycin in vitrectomy infusion solution and evaluation of retinal toxicity.

Authors:  H Borhani; G A Peyman; H Wafapoor
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

5.  Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model.

Authors:  S B Duffull; E J Begg; S T Chambers; M L Barclay
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 6.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 7.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Isolation and characterisation of ΦcrAss002, a crAss-like phage from the human gut that infects Bacteroides xylanisolvens.

Authors:  Emma Guerin; Andrey N Shkoporov; Stephen R Stockdale; Joan Colom Comas; Ekaterina V Khokhlova; Adam G Clooney; Karen M Daly; Lorraine A Draper; Niamh Stephens; Dimitri Scholz; R Paul Ross; Colin Hill
Journal:  Microbiome       Date:  2021-04-12       Impact factor: 14.650

Review 9.  Central nervous system infections: a critical care approach.

Authors:  W C Ziai; R G Geocadin
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 6.030

10.  Pruritus: a useful sign for predicting the haemodynamic changes that occur following administration of vancomycin.

Authors:  Massimo Bertolissi; Flavio Bassi; Roberta Cecotti; Carlo Capelli; Francesco Giordano
Journal:  Crit Care       Date:  2002-04-25       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.